Clinical Trial Update: Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dasatinib in recurrent or persistent ovarian, fallopian tube, endometrial, or peritoneal cancers; study terminated with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Clear Cell Adenocarcinoma
• Fallopian Tube Carcinoma
• Ovarian Carcinoma
• Ovarian Clear Cell Cystadenocarcinoma
• Peritoneal Carcinoma
• Uterine Corpus Cancer

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2019-05-17